Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1955 Jan;34(1):115–120. doi: 10.1172/JCI103053

HEMODYNAMIC EFFECTS OF 1-HYDRAZINOPHTHALAZINE IN PATIENTS WITH ARTERIAL HYPERTENSION 1

George G Rowe 1,2,2, John H Huston 1,2,3, George M Maxwell 1,2, Archer P Crosley Jr 1,2, Charles W Crumpton 1,2, Beryl Welch 1,2, Audrey Peterson 1,2
PMCID: PMC438591  PMID: 13221661

Full text

PDF
115

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASSALI N. S., KAPLAN S., OIGHENSTEIN S., SUYEMOTO R. Hemodynamic effects of 1-hydrazinophthalazine (apresoline) in human pregnancy: results of intravenous administration. J Clin Invest. 1953 Oct;32(10):922–930. doi: 10.1172/JCI102817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. CRAVER B. N., BARRETT W., CAMERON A., YONKMAN F. F. The activities of 1-hydrazinophthalazine (Ba-5968); a hypotensive agent. J Am Pharm Assoc Am Pharm Assoc. 1951 Nov;40(11):559–564. doi: 10.1002/jps.3030401109. [DOI] [PubMed] [Google Scholar]
  3. DEXTER L., DOW J. W., HAYNES F. W., WHITTENBERGER J. L., FERRIS B. G., GOODALE W. T., HELLEMS H. K. Studies of the pulmonary circulation in man at rest; normal variations and the interrelations between increased pulmonary blood flow, elevated pulmonary arterial pressure, and high pulmonary 'capillary" pressures. J Clin Invest. 1950 May;29(5):602–613. doi: 10.1172/JCI102297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. FREIS E. D., MacKAY J. C., OLIVER W. F. The effect of sympatholytic drugs on the cardiovascular responses to epinephrine and norepinephrine in man. Circulation. 1951 Feb;3(2):254–259. doi: 10.1161/01.cir.3.2.254. [DOI] [PubMed] [Google Scholar]
  5. HAFKENSCHIEL J. H., FRIEDLAND C. K. The effects of 1-hydrazinophthalazine on cerebral blood flow, vascular resistance, oxygen uptake and jugular oxygen tension in hypertensive subjects. J Clin Invest. 1953 Jul;32(7):655–660. doi: 10.1172/JCI102778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. LOMBARDO T. A., ROSE L., TAESCHLER M., TULUY S., BING R. J. The effect of exercise on coronary blood flow, myocardial oxygen consumption and cardiac efficiency in man. Circulation. 1953 Jan;7(1):71–78. doi: 10.1161/01.cir.7.1.71. [DOI] [PubMed] [Google Scholar]
  7. MOYER J. H., HANDLEY C. A., HUGGINS R. A. Some pharmacodynamic effects of 1-hydrazinophthalazine (C-5968) with particular reference to renal function and cardiovascular response. J Pharmacol Exp Ther. 1951 Dec;103(4):368–376. [PubMed] [Google Scholar]
  8. MOYER J. H. Hydrallazine (apresoline) hydrochloride; pharmacological observations and clinical results in the therapy of hypertension. AMA Arch Intern Med. 1953 Apr;91(4):419–439. doi: 10.1001/archinte.1953.00240160005002. [DOI] [PubMed] [Google Scholar]
  9. WALKER H. A., WILSON S., ATKINS E. C., GARRETT H. E., RICHARDSON A. P. The effect of 1-hydrazinophthalazine (C-5968) and related compounds on the cardiovascular system of dogs. J Pharmacol Exp Ther. 1951 Apr;101(4):368–378. [PubMed] [Google Scholar]
  10. WILKINSON E. L., BACKMAN H., HECHT H. H. Cardiovascular and renal adjustments to a hypotensive agent (l'hydrazinophthalazine: Ciba BA-5968: apresoline). J Clin Invest. 1952 Oct;31(10):872–879. doi: 10.1172/JCI102674. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES